9 results match your criteria: "Saint-Eloi Hospital and Montpellier University Hospital[Affiliation]"
Background: Primary Sjögren's syndrome (pSS) is an autoimmune disease with increased risk of infections. Here, we assessed whether pSS patients were at higher risk of hospitalization for community and opportunistic infections.
Methods: We selected newly hospitalized pSS patients between 2011 and 2018, through a nationwide population-based retrospective study using the French Health insurance database.
A comparative study of classic and HIV-viremic and aviremic AIDS Kaposi sarcoma.
AIDS
March 2021
Department of Infectiology, Inserm U1175, Saint Eloi Hospital and Montpellier University Hospital.
Background: Kaposi sarcoma in people living with HIV (PLHIV) is the most common AIDS-associated malignancy. There is increased interest in Kaposi sarcoma in PLHIV with controlled HIV viremia.
Objectives: To describe Kaposi sarcoma occurring in PLHIV despite virological control and to compare their clinical presentations with viremic AIDS-Kaposi sarcoma (AIDS-KS) and classic Kaposi sarcoma (CKS).
Clinical and pathological dermatological features of deficiency of adenosine deaminase 2: A multicenter, retrospective, observational study.
J Am Acad Dermatol
December 2020
Sorbonne Université, Faculté de Médecine, Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, Service de médecine interne, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris, France.
PASS: a rare syndrome within the autoinflammatory diseases that still lacks a genetic marker.
J Eur Acad Dermatol Venereol
September 2020
Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, Montpellier, France.
Low Prevalence of GSC Gene Mutations in a Large Cohort of Predominantly Caucasian Patients with Hidradenitis Suppurativa.
J Invest Dermatol
October 2020
Laboratory of Genetic Skin Diseases, INSERM UMR1163 Imagine Institute, Paris, France; Paris University, Paris, France; European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany; Department of Genetics, Necker-Enfants Malades Hospital, AP-HP, Paris, France. Electronic address:
Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis.
Acta Derm Venereol
March 2019
Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, 34295 Montpellier, France.
Anti-transcriptional intermediary factor-1γ (TIF-1γ) autoantibody may be associated with cancer in adult patients with dermatomyositis. The aim of this study was to evaluate the risk of cancer in the presence of anti-TIF-1γ autoantibody in adult dermatomyositis. A comprehensive database search of EMBASE, MEDLINE and the Cochrane Library up to May 2018 was performed using the main key words "dermatomyositis", ""myositis", "inflammatory myopathies" and "anti-TIF-1".
View Article and Find Full Text PDFA decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience.
Eur J Hum Genet
July 2018
Laboratory of Rare and Autoinflammatory Genetic Diseases and CEREMAIA, Montpellier University Hospital, Montpellier, France.
Article Synopsis
- DADA2 is a newly identified autoinflammatory disorder that requires genetic testing for diagnosis; a study analyzed 66 patients suspected of having DADA2.
- Out of the patients tested, 19.6% had harmful mutations in the ADA2 gene, with seven mutations being newly discovered; symptoms included fever, vasculitis, and neurological issues.
- The study developed a decision tree to guide genetic testing recommendations, suggesting key criteria like typical symptoms, inflammation markers, and attack patterns to improve diagnosis efficiency.
Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients.
J Eur Acad Dermatol Venereol
July 2018
Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, Montpellier, France.
Background: Identification of myositis-specific autoantibodies (MSAs) for dermatomyositis (DM) could allow the characterization of an antibody-associated clinical phenotype.
Objective: We sought to define the clinical phenotype of DM and the risk of cancer, interstitial lung disease (ILD) and calcinosis based on MSA.
Methods: A 3.
Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients.
J Am Acad Dermatol
September 2017
Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, Montpellier, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U1058, Montpellier, France; Regional Center of Competence for Rare Skin Disorders, Montpellier, France. Electronic address:
Background: Data on long-term topical sirolimus treatment of the cutaneous manifestations of tuberous sclerosis complex are rare.
Objective: To evaluate the long-term benefit and tolerance of topical 1% sirolimus in tuberous sclerosis complex.
Methods: In this 18-month prospective single-center study, 1% sirolimus cream was applied daily to facial angiofibromas (FAs), fibrous cephalic plaques (FCPs), shagreen patches, hypomelanotic macules, and ungual fibromas.